Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers

Radiology

Volumn 266, Issue 2, 2013, Pages 583-591

  Shaffer, Jennifer L ^a   Petrella, Jeffrey R ^a   Sheldon, Forrest C ^a   Choudhury, Kingshuk Roy ^a   Calhoun, Vince D ^c,d   Edward Coleman, R ^a   Murali Doraiswamy, P ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c MIND RESEARCH NETWORK   (United States)

^d University of New Mexico   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18;

AGE; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEPENDENT VARIABLE; DIAGNOSTIC TEST ACCURACY STUDY; EDUCATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; INDEPENDENT COMPONENT ANALYSIS; INFORMATION PROCESSING; INFORMED CONSENT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

AGED; ALZHEIMER DISEASE; AREA UNDER CURVE; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84873361594     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12120010     Document Type: Article

References (46)

1. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42(11):1097-1105.
2. Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 2003;226(2):315-336.
3. Weiner MW, Aisen PS, Jack CR, et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 2010;6(3):202-211.e7.
4. Alzheimer's Association. 2010 Alzheimer's disease facts and fgures. Alzheimers Dement 2010;6(2):158-194.
5. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60(8):1119-1122.
6. Trojanowski JQ. Searching for the biomarkers of Alzheimer's. Pract Neurol 2004;3:30-34.
7. Hinrichs C, Singh V, Xu G, Johnson SC; Alzheimers Disease Neuroimaging Initiative. Predictive markers for AD in a multi-modality framework: an analysis of MCI progression in the ADNI population. Neuroimage 2011;55(2):574-589.
8. Jack CR Jr, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133(11):3336-3348.
9. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents earlystage Alzheimer disease. Arch Neurol 2001;58(3):397-405.
10. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG. Aging, memory, and mild cognitive impairment. Int Psychogeriatr 1997;9(suppl 1):65-69.
11. Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Trojanowski JQ. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol Aging 2010;32(12):2322.e19-e27.
12. Plant C, Teipel SJ, Oswald A, et al. Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease. Neuroimage 2010;50(1):162-174.
13. Walhovd KB, Fjell AM, Brewer J, et al. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol 2010;31(2):347-354.
14. Jagust WJ, Eberling JL, Wu CC, et al. Brain function and cognition in a community sample of elderly Latinos. Neurology 2002;59(3):378-383.
15. De Santi S, De Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22(4):529-539.
16. Walhovd KB, Fjell AM, Dale AM, et al. Multimodal imaging predicts memory performance in normal aging and cognitive decline. Neurobiol Aging 2010;31(7):1107-1121.
17. Alzheimer's Disease Neuroimaging Initiative. About the study. http://adni.loni.ucla.edu/about/about-the-study/. Published 2010. Accessed September 19, 2010.
18. Cui Y, Liu B, Luo S, et al. Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors. PLoS ONE 2011;6(7):e21896.
19. Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE; Alzheimer's Disease Neuroimaging Initiative. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry 2011;68(9):961-969.
20. Ewers M, Walsh C, Trojanowski JQ, et al. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 2012;33(7):1203-1214.
21. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010;75(3):230-238.
22. Chen K, Ayutyanont N, Langbaum JBS, et al. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage 2011;56(1):52-60.
23. McEvoy LK, Holland D, Hagler DJ Jr, et al. Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis. Radiology 2011;259(3):834-843.
24. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK; Alzheimer's Disease Neuroimaging Initiative. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 2011;77(17):1619-1628.
25. Calhoun VD, Adali T, Giuliani NR, Pekar JJ, Kiehl KA, Pearlson GD. Method for multimodal analysis of independent source differences in schizophrenia: combining gray matter structural and auditory oddball functional data. Hum Brain Mapp 2006;27(1):47-62.
26. Liu J, Pearlson G, Windemuth A, Ruano G, Perrone-Bizzozero NI, Calhoun V. Combining fMRI and SNP data to investigate connections between brain function and genetics using parallel ICA. Hum Brain Mapp 2009;30(1):241-255.
27. Rachakonda S, Liu J, Calhoun V. Fusion ICA toolbox (FIT) manual. Albuquerque, NM: The MIND Research Network, University of New Mexico, 2008.
28. Alzheimer's Disease Neuroimaging Initiative. Procedures manual. http://adni.loni.ucla. edu/research/protocols/. Published 2011. Accessed February 8, 2011.
29. Alzheimer's Disease Neuroimaging Initiative. Image data. http://adni.loni.ucla.edu/aboutdata-samples/image-data/. Published 2010. Accessed September 19, 2010.
30. Ashburner J, Friston KJ. Voxel-based morphometry: the methods. Neuroimage 2000;11(6 Pt 1):805-821.
31. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxelbased morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001;14(1 Pt 1):21-36.
32. Smith SM, Jenkinson M, Woolrich M W, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(suppl 1):S208-S219.
33. Woolrich M W, Jbabdi S, Patenaude B, et al. Bayesian analysis of neuroimaging data in FSL. Neuroimage 2009;45(1 suppl):S173-S186.
34. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65(4):403-413.
35. Alzheimer's Disease Neuroimaging Initiative. Biospecimens protocols. http://adni.loni.ucla.edu/research/protocols/biospecimensprotocols/. Published 2010. Accessed September 19, 2010.
36. McCullagh P, Nelder J. Generalized linear models. 2nd ed. Boca Raton, Fla: CRC Press, 1989.
37. Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer's disease. Nat Med 2004;10(suppl):S34-S41.
38. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009;73(4):294-301.
39. Reiman EM, Chen K, Alexander GE, et al. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A 2005;102(23):8299-8302.
40. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25(34):7709-7717.
41. Buckner RL, Vincent JL. Unrest at rest: default activity and spontaneous network correlations. Neuroimage 2007;37(4):1091-1096; discussion 1097-1099.
42. Karow DS, McEvoy LK, Fennema-Notestine C, et al. Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology 2010;256(3):932-942.
43. Fan Y, Resnick SM, Wu X, Davatzikos C. Structural and functional biomarkers of prodromal Alzheimer's disease: a high-dimensional pattern classification study. Neuroimage 2008;41(2):277-285.
44. Calhoun VD, Adali T. Feature-based fusion of medical imaging data. IEEE Trans Inf Technol Biomed 2009;13(5):711-720.
45. Jack CR, Barkhof F, Bernstein MA, et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement 2011;7(4):474-485.e4.
46. Medina D, De Toledo-Morrell L, Urresta F, et al. White matter changes in mild cognitive impairment and AD: a diffusion tensor imaging study. Neurobiol Aging 2006;27(5):663-672.